News from Zentiva


February 10, 2022    /    News

Soňa Porubská’s New Role as the Global Head of Corporate Affairs

PRAGUE – February 10, 2022: After 10 years as General Manager Zentiva Czech Republic and Slovakia, Soňa Porubská moves to a new position in the global executive team of Zentiva – she becomes the Head of Corporate Affairs and Strategic Franchises. She hands over the role of the General Manager to the next-generations talent Boris Sananes.

Soňa Porubská was the General Manager of the Czech Republic and Slovakia since 2011. Under her guidance, Zentiva has become the most important supplier of medicines to Czech citizens. With R&D and a huge medicines manufacturing site in Prague, Zentiva makes a wonderful contribution to public health in Czechia and across the whole of Europe. In 2021, 17 new Zentiva medicine brands were launched, including cardiovascular treatments, oncology treatments, asthma treatments, and diabetes treatments. The company also introduced a new innovative treatment for chronic wounds, Amnioderm. Zentiva continues to make an important contribution to the fight against the Covid-19 pandemic through its life-saving hospital medicines supply. Our company received an Award for an outstanding contribution to the fight against the Covid-19 pandemic by the Ministry of Industry and Trade.

Soňa Porubská is an accomplished leader and a role model. Her leadership is characterized by a strong focus on helping patients, supported by transparency and trust within the teams she has built. “A good leader has to be open-minded and listen to his/her colleagues. One must be capable of developing the potential of others and making important but often tough decisions.” Soňa Porubská has been awarded numerously for her splendid work in the Czech Republic and Slovakia. Last time by the Hospodařské noviny, who have included her among the TOP 20 female managers of the year in the Czech Republic for the fourth time, or the Forbes magazine, where she appeared in the prestigious list of the TOP 21 CEOs of 2021.

In her new global role as the Head of Corporate Affairs and Strategic Franchises, Soňa will be responsible for growing the collaboration between Zentiva, the Czech Government, the Romanian Government, and Governments across Europe to help strengthen sustainable manufacturing, development, and supply of high-quality affordable medicines in Europe. Sona will also be returning to the board of the Czech Association of Pharmaceutical Companies (ČAFF). In 2022, she will concentrate on the Presidency of the Czech Republic in the Council of the EU which will happen in the second half of the year. In her Strategic Franchises role, she will guide Zentiva’s medicines portfolio commercialization strategy, allowing Zentiva to focus its energy and make the biggest difference possible to the patients in Europe.

I am looking forward to the new challenges my new global role brings. Zentiva is in a phase of rapid growth and I am excited to help the company move forward and provide high-quality affordable medicine to even more patients in Europe and beyond. I will also stay passionately close to our teams, customers, and stakeholders in both Czechia and Slovakia,” said Soňa Porubská about her new position.

About Zentiva

Zentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,700 people and a network of production sites - including flagship sites in Prague, Bucharest, and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support people’s daily healthcare needs. At Zentiva it is our aspiration that healthcare should be a right and not a privilege. More than ever, people need better access to high-quality affordable medicines and healthcare. We work in partnership with physicians, pharmacists, wholesalers, regulators, and governments to provide the everyday solutions that we all depend on.

Media Contact

Mounira Lemoui
Head of Communications
U kabelovny 529/16, Dolní Měcholupy, 102 00 Prague 10
Mobil: (+420) 727 873 159